IL325202A - נוגדנים נגד סיבים (פיברילים) - Google Patents

נוגדנים נגד סיבים (פיברילים)

Info

Publication number
IL325202A
IL325202A IL325202A IL32520225A IL325202A IL 325202 A IL325202 A IL 325202A IL 325202 A IL325202 A IL 325202A IL 32520225 A IL32520225 A IL 32520225A IL 325202 A IL325202 A IL 325202A
Authority
IL
Israel
Prior art keywords
seq
monoclonal antibody
domain
sequence identity
humanised
Prior art date
Application number
IL325202A
Other languages
English (en)
Original Assignee
Immutrin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2308898.2A external-priority patent/GB202308898D0/en
Priority claimed from GBGB2308884.2A external-priority patent/GB202308884D0/en
Application filed by Immutrin Ltd filed Critical Immutrin Ltd
Publication of IL325202A publication Critical patent/IL325202A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL325202A 2023-06-14 2024-06-13 נוגדנים נגד סיבים (פיברילים) IL325202A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2308898.2A GB202308898D0 (en) 2023-06-14 2023-06-14 Anti-fibril antibodies
GBGB2308884.2A GB202308884D0 (en) 2023-06-14 2023-06-14 Anti-fibril antibodies
PCT/EP2024/066449 WO2024256583A1 (en) 2023-06-14 2024-06-13 Anti-fibril antibodies

Publications (1)

Publication Number Publication Date
IL325202A true IL325202A (he) 2026-02-01

Family

ID=91580895

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325202A IL325202A (he) 2023-06-14 2024-06-13 נוגדנים נגד סיבים (פיברילים)

Country Status (8)

Country Link
EP (1) EP4727650A1 (he)
KR (1) KR20260026033A (he)
CN (1) CN121487964A (he)
AU (1) AU2024304161A1 (he)
CL (1) CL2025003893A1 (he)
IL (1) IL325202A (he)
MX (1) MX2025014924A (he)
WO (1) WO2024256583A1 (he)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
ATE352612T1 (de) 1990-08-29 2007-02-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
US10344080B2 (en) * 2013-12-20 2019-07-09 Neurimmune Holding Ag Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor
EP3101131B1 (en) * 2014-01-29 2020-08-19 KM Biologics Co., Ltd. Anti-transthyretin humanized antibody
CU24731B1 (es) * 2017-10-06 2025-01-15 Prothena Biosciences Ltd Anticuerpos anti-transtiretina
EP4237005A4 (en) * 2020-10-28 2024-10-09 Novo Nordisk A/S ANTI-TRANSTHYRETIN ANTIBODIES AND METHODS OF USE THEREOF

Also Published As

Publication number Publication date
MX2025014924A (es) 2026-02-03
WO2024256583A1 (en) 2024-12-19
KR20260026033A (ko) 2026-02-25
CL2025003893A1 (es) 2026-01-30
AU2024304161A1 (en) 2025-12-11
CN121487964A (zh) 2026-02-06
EP4727650A1 (en) 2026-04-22

Similar Documents

Publication Publication Date Title
CN110799531B (zh) 抗PHF-tau抗体及其用途
KR102866306B1 (ko) 신경 성장 인자에 대한 단일 클론 항체, 및 이의 코딩 유전자 및 용도
RU2770209C2 (ru) Терапевтические антитела против лиганда cd40
CN108350079B (zh) 用于治疗神经学和其它病症的结合激动剂
NZ717476A (en) Anti-garp protein and uses thereof
US11440953B2 (en) Anti-abeta antibodies
US20230174669A1 (en) Anti-CD98 Antibodies And Uses Thereof
AU2019395325B2 (en) Anti-Alpha-Synuclein Antibodies and Uses Thereof
CN120712286A (zh) 抗体、抗原结合片段和使用方法
WO2019001559A1 (zh) 抗gitr抗体、其抗原结合片段及其医药用途
IL325202A (he) נוגדנים נגד סיבים (פיברילים)
JP2025525348A (ja) λサブクラスの免疫グロブリン軽鎖の立体配座特異的エピトープを標的とするモノクローナル抗体
US20250101087A1 (en) Anti-amyloid beta antibodies and methods of using the same
WO2025117530A2 (en) Tmem106b(120-254) aggregate-binding antibody
WO2025241702A1 (zh) 靶向hla-g的抗体或其抗原结合片段及其应用
WO2026033259A1 (en) Antibodies for treating neurological and neurovascular disorders
CN115443147A (zh) 抗体的皮下吸收和生物利用度
HK40054347B (zh) 抗alpha-突触核蛋白抗体及其用途
HK1166331B (en) Use of an anti-tau ps422 antibody for the treatment of brain diseases
HK1166331A1 (en) Use of an anti-tau ps422 antibody for the treatment of brain diseases